Literature DB >> 11823036

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Amelia Bartholomew1, Cord Sturgeon, Mandy Siatskas, Karen Ferrer, Kevin McIntosh, Sheila Patil, Wayne Hardy, Steve Devine, David Ucker, Robert Deans, Annemarie Moseley, Ronald Hoffman.   

Abstract

OBJECTIVE: Mesenchymal stem cells (MSCs), multipotential cells that reside within the bone marrow, can be induced to differentiate into various components of the marrow microenvironment, such as bone, adipose, and stromal tissues. The bone marrow microenvironment is vital to the development, differentiation, and regulation of the lymphohematopoietic system. We hypothesized that the activities of MSCs in the bone marrow microenvironment might also include immunomodulatory effects on lymphocytes.
METHODS: Baboon MSCs were tested in vitro for their ability to elicit a proliferative response from allogeneic lymphocytes, to inhibit an ongoing allogeneic response, and to inhibit a proliferative response to potent T-cell mitogens. In vivo effects were tested by intravenous administration of donor MSCs to MHC-mismatched recipient baboons prior to placement of autologous, donor, and third-party skin grafts.
RESULTS: MSCs failed to elicit a proliferative response from allogeneic lymphocytes. MSCs added into a mixed lymphocyte reaction, either on day 0 or on day 3, or to mitogen-stimulated lymphocytes, led to a greater than 50% reduction in proliferative activity. This effect could be maximized by escalating the dose of MSCs and could be reduced with the addition of exogenous IL-2. In vivo administration of MSCs led to prolonged skin graft survival when compared to control animals: 11.3 +/- 0.3 vs 7 +/- 0.
CONCLUSIONS: Baboon MSCs have been observed to alter lymphocyte reactivity to allogeneic target cells and tissues. These immunoregulatory features may prove useful in future applications of tissue regeneration and stem cell engineering.

Entities:  

Mesh:

Year:  2002        PMID: 11823036     DOI: 10.1016/s0301-472x(01)00769-x

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  646 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

2.  Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Authors:  Won Sik Lee; Yasuhiro Suzuki; Scott S Graves; Mineo Iwata; G M Venkataraman; Marco Mielcarek; Laura J Peterson; Susumu Ikehara; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-10       Impact factor: 5.742

3.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

4.  Changes of the Functional Capacity of Mesenchymal Stem Cells due to Aging or Age-Associated Disease - Implications for Clinical Applications and Donor Recruitment.

Authors:  Günter Lepperdinger; Regina Brunauer; Robert Gassner; Angelika Jamnig; Frank Kloss; Gerhard Thomas Laschober
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

5.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

6.  Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment.

Authors:  Vladimir Holan; Barbora Hermankova; Pavla Bohacova; Jan Kossl; Milada Chudickova; Michaela Hajkova; Magdalena Krulova; Alena Zajicova; Eliska Javorkova
Journal:  Stem Cell Rev Rep       Date:  2016-12       Impact factor: 5.739

Review 7.  Mesenchymal stem cells in the treatment of spinal cord injuries: A review.

Authors:  Venkata Ramesh Dasari; Krishna Kumar Veeravalli; Dzung H Dinh
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

9.  Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes.

Authors:  Stéphane Vigouroux; Eric Yvon; Hans-Joachim Wagner; Ettore Biagi; Gianpietro Dotti; Uluhan Sili; Cecilia Lira; Cliona M Rooney; Malcolm K Brenner
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 10.  Mesenchymal stem cell treatments in rheumatology: a glass half full?

Authors:  Alan Tyndall
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.